NASDAQ · ACOG

Alpha Cognition Inc.

$8.58 +$0.68 (+8.61%) 1D Market open

Key Metrics

$172.02M
Market cap
P/E · TTM
$10.83M
Revenue · TTM
−$25.14M
Net income
EPS · TTM $-1.57
Dividend yield
Free cash flow −$30.37M
Beta · 1Y 1.09
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Apr 7
    The stock moved +12.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 7
  • Feb 6
    The stock moved +13.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 6

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$172.02M
Enterprise value
Shares outstanding21.8M
52-wk range$4.50 – $10.15
Avg volume · 20D84.7K
Net cash
Book value / share$3.59
IndustryBiological Products, (No Diagnostic Substances)
ExchangeNASDAQ
About Alpha Cognition Inc.
IPO dateJun 9, 2021
Employees71

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S15.89
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -250.1%
Net -232.2%
FCF -280.5%
ROE / ROIC -50.8% · —

Financial Health

Current ratio12.64
Quick ratio11.52
Debt / equity
Debt / EBITDA
Net cash
Working capital$63.13M

Cash Flow · TTM

Operating CF −$30.13M
Capex −$231.54K
Free cash flow −$30.37M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

6.6
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings